Complimentary Webinar:


Guiding Precision Medicine:

Innovative Advanced Imaging to Identify the Right Treatment for Patients and
Prevent Late-Stage Failures

July 29, 2021 |  10am EST

Click below to register


About the Webinar:

This webinar showcases the innovative use of multiplexed immunofluorescence and subsequent imaging, revealing a vast potential for precision medicine: to quickly identify the right treatment for the individual patient, and limit or prevent late-stage clinical trial failures. 

Used in conjunction with traditional H&E (hematoxylin and eosin) staining, same-slide multiplex immunofluorescence (mIF) provides the whole-tissue, detailed look at the tumor microenvironment while preserving the tissue morphology. 

Previous immunohistochemistry-based techniques are often limited to 1-2 biomarkers, serving as single-marker approaches to multi-faceted problems. Picking multiple biomarkers, and the right biomarkers, while utilizing less biopsy material provides more answers for clinicians and pathologists. Ultimately, that arms clinical trials with more advanced information and better predicts how patients will respond to certain treatments. 

This webinar will provide a demonstration of a streamlined unique workflow on whole-slide imaging on a single tissue slide of an 8-plex mIF and traditional same-slide H&E fusion for a comprehensive tissue immunophenotyping analysis. 

Use cases will be presented, followed by audience Q&A on the technology, impacts and implementations.

Learning objectives:

  • How a high-throughput, high-plex (Immuno-8) staining and mIF assay development can more accurately predict response
  • How whole-slide image analysis of the tumor microenvironment, using barcoding technology, can provide insight into specific cancer types
  • How advanced AI-driven image analysis can be applied to discover cell types, populations and morphological context



Florian Leiss, PhD
VP Digital Health Strategies

Florian Leiss is VP Digital Health Strategies at Ultivue. He is responsible for digital and data-driven offerings and image analysis. Florian has been working for 10+ years in software development for healthcare to make AI-powered CDx in oncology a reality, to support radiologists with routine reporting, or to empower pathologists with image analysis at AstraZeneca, Smart Reporting and Definiens. He holds PhDs in neuroscience and philosophy.

Kirsteen Maclean, PhD
Director of Biomarker and Translational Strategy

Kirsty has 20 years of leadership experience addressing academic, clinical, biotechnology, clinical research organizations (CRO) and pharmaceutical industries through clinical/technical communication, sales support, and market intelligence. Most recently, Kirsty was instrumental in overseeing commercial applications for CodexDNA enabling rapid antibody development for vaccines and novel therapeutics using an automated cloning platform. Previously Kirsty held leadership roles in commercial development and scientific communications at Definiens (now part of AstraZeneca), Nanostring Technologies and ThermoFisher Scientific. She holds a PhD in Hematology and a BS (hons) in Biochemistry


Mark Rees, PhD
Vice President, Corporate Development

Mark Rees, PhD, joined Ultivue’s executive team in January as Vice President of Corporate Development. Mark has 21+ years of leadership experience in Scientific Affairs and Business development within research and diagnostic markets. Most recently, Mark was instrumental in creating a diagnostic division for StatLab, launching a full portfolio of IHC reagents, automated staining platforms as well as a patented reference standard control technology for tissue pathology. Previously Mark held leadership roles in commercial development, Scientific Affairs and R&D at Enzo Lifesciences, Leica Biosystems NA (Danaher) and Novocastra Laboratories.

He holds a PhD in Molecular Biology & Microbiology, MS in Industrial Microbiology and a BS (hons) in Biochemistry, graduating from Newcastle University Medical School, England UK


About Ultivue:

Ultivue provides researchers in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approaches strengthen and accelerate biomarker discovery and drug development programs. To learn more, visit


There is no fee to attend, but registration is required.